

PROVINCIAL FUNDING SUMMARY

Pazopanib hydrochloride (Votrient) for Soft Tissue Sarcoma (STS)

pERC Recommendation: Does Not Recommend
For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: December 14, 2012

This information is current as of August 8, 2017. The use of this document is directed by [pCODR's Terms of Use](#).

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Not funded		
AB	Not funded		
SK	Not funded		
MB	Under provincial consideration*		
ON	Not funded		
NS	Not funded		
NB	Not funded		
NL	Not funded		
PEI	Not funded		

**Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pricing Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.